Condition
Natural Killer Cell Malignancies
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Terminated1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03314974Phase 2Recruiting
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT02722668Phase 2Completed
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
NCT02991898Phase 2Terminated
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Showing all 3 trials